课题基金 / 基金详情

What is the best way for healthcare professionals to communicate changes in estimated risk of breast cancer?

What is the best way for healthcare professionals to communicate changes in estimated risk of breast cancer?
医疗保健专业人员传达乳腺癌估计风险变化的最佳方式是什么?
批准号:
2456973
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2020
资助国家:
英国
项目状态:
未结题
起止时间:
2020 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Risk estimation models for common multifactorial diseases such as breast cancer are often used, e.g. in Family History Clinics to inform decisions about prevention options. Their use is increasing, e.g. 58,000 women who attended routine breast-screening were provided risk estimates in the PROCAS study (1). A challenge for the use of these risk estimation models in clinical practice is that an individual's risk estimate can change, for several reasons. First, new versions of risk estimation algorithms, e.g., Tyrer-Cuzick model are updated. Second, these models can include more information sources: historically, they were based on self-reported family history and hormone-related factors, e.g. parity. They can now include information about breast density and Single Nucleotide Polymorphisms (SNPs) (2). Thirdly, estimates of lifetime breast cancer risk decrease with age, as each individual is older at later timepoints. The extent of change can be large. In the Family History Risk (FH-Risk) study, 914 Manchester-based women received risk estimates between 1993-2010. They were told their risk was "high", "moderate", "average" or "below average"; women at high or moderate risk were offered prevention options, i.e. enhanced screening or chemoprevention (3). A sub-sample of 106 women had their risks re-evaluated using the latest version of the Tyrer-Cuzick model, including mammographic density and 18 SNPs. Of these 106 women, the lifetime risk of 53 women decreased by one or more risk categories (e.g. from high to moderate). Forty women did not change category whilst the risk of 13 women increased. There is a dearth of research exploring the impact of receiving revised risk estimates for any disease: a scoping search failed to identify any such studies. Whilst there appears to be little emotional impact of receiving breast cancer risk estimates (4), many people do not trust the estimates they received (5). Receiving revised risk estimates may further undermine trust in healthcare professionals or credibility of risk estimation, as changes may produce revised management plans.This PhD will: (a) identify the key issues for women who receive revised risk estimates; (b) develop materials to support consultations involving revised risk estimates, and (c) assess emotional impact, understanding of risk information, trust in healthcare professionals, and views of prevention options of women in the Family History Risk study. This research will produce an evidence base to help healthcare professionals communicate better with women about changes in estimated breast cancer risk, and more widely, changing risk of other diseases, e.g. Cardiovascular Disease.(1) Evans DG et al, Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. NIHR Programme Grants for Applied Research, 2016: 4(11).(2) Evans DGR et al, Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. Breast Cancer Res Tr 2019; 176(1): 141-148.(3) Evans DG et al, The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study. J Med Genet. 2017; 54(2):111-113.(4) French DP et al. Psychological impact of providing women with personalised 10-year breast cancer risk estimates. Br J Cancer 2018; 118(12): 1648-1657.(5) Bayne M et al. (in press) Effect of interventions including provision of personalised cancer risk information on accuracy of risk perception and psychological responses: a systematic review and meta-analysis. Pat Ed Couns. DOI: 10.1016/j.pec.2019/08/010
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/s41416-022-01944-x
发表时间: 2022-11
期刊: British journal of cancer
影响因子: 8.8
作者: [Woof VG, Howell A, McWilliams L, Gareth Evans D, French DP]
通讯作者: French DP
DOI: 10.1111/bjhp.12678
发表时间: 2023
期刊: British journal of health psychology
影响因子: 7.9
作者: [Woof VG]
通讯作者: Woof VG
国内基金
海外基金
BEST3经MEKK2/3-LATS1/2-YAP/TAZ信号轴阻断子宫内膜基质 细胞自噬在宫腔粘连中的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    陈醒
  • 依托单位:
Clic1 与 Best1 氯离子通道协同调节视神经再生及调 控机制
  • 批准号:
    2024JJ5471
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    王树超
  • 依托单位:
Best1通道调控缺血性脑卒中的兴奋-抑制平衡
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
  • 依托单位:
BEST4作为Notch2-Hes4轴的关键靶分子通过拮抗STAT3二聚化逆转EMT抑制结直肠癌转移的作用和机制研究
  • 批准号:
    82103539
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    王紫静
  • 依托单位: